Promising new combo targets leukemia cells without harming healthy ones

NCT ID NCT01409161

First seen Jan 04, 2026 · Last updated May 22, 2026 · Updated 25 times

Summary

This study tests whether combining two chemotherapy drugs (tretinoin and arsenic trioxide) with an immunotherapy drug (gemtuzumab ozogamicin) works better than the two drugs alone for people with a specific type of leukemia called acute promyelocytic leukemia. About 151 newly diagnosed patients will take part. The goal is to see if the combination can stop the cancer from coming back longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE PROMYELOCYTIC LEUKEMIA WITH PML-RARA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-••••

    Contact

  • MD Anderson Regional Care Center-Bay Area

    RECRUITING

    Nassau Bay, Texas, 77058, United States

    Contact Phone: •••-•••-••••

    Contact

  • MD Anderson Regional Care Center-Katy

    RECRUITING

    Houston, Texas, 77094, United States

    Contact Phone: •••-•••-••••

    Contact

  • MD Anderson Regional Care Center-Sugar Land

    RECRUITING

    Sugar Land, Texas, 77478, United States

    Contact Phone: •••-•••-••••

    Contact

  • MD Anderson Regional Care Center-The Woodlands

    RECRUITING

    The Woodlands, Texas, 77384, United States

    Contact Phone: •••-•••-••••

    Contact

Conditions

Explore the condition pages connected to this study.